Identification of Special AT-Rich Sequence Binding Protein 1 as a Novel Tumor Antigen Recognized by CD8+ T Cells: Implication for Cancer Immunotherapy

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Wang, Mingjun ^a,b   Yin, Bingnan ^a   Matsueda, Satoko ^b   Deng, Lijuan ^a   Li, Ying ^b   Zhao, Wei ^a   Zou, Jia ^a   Li, Qingtian ^a   Loo, Christopher ^a   Wang, Rong Fu ^a,b   Wang, Helen Y ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT RICH SEQUENCE BINDING PROTEIN 1; EPITOPE; GAMMA INTERFERON; MESSENGER RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR CELL DESTRUCTION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; MATRIX ATTACHMENT REGION BINDING PROTEINS; NEOPLASMS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84874293919     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056730     Document Type: Article

References (47)

1. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
2. Novellino L, Castelli C, Parmiani G, (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer immunology, immunotherapy: CII 54: 187-207.
3. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, et al. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 5323-5337.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine 363: 411-422.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 363: 711-723.
6. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, et al. (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England journal of medicine 364: 2119-2127.
7. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T, (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409.
8. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404.
9. Rosenberg SA, (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nature reviews Clinical oncology 8: 577-585.
10. Lesterhuis WJ, Haanen JB, Punt CJ, (2011) Cancer immunotherapy-revisited. Nature reviews Drug discovery 10: 591-600.
11. Di Lorenzo G, Buonerba C, Kantoff PW, (2011) Immunotherapy for the treatment of prostate cancer. Nature reviews Clinical oncology 8: 551-561.
12. Beatty GL, Vonderheide RH, (2008) Telomerase as a universal tumor antigen for cancer vaccines. Expert review of vaccines 7: 881-887.
13. Andersen MH, Svane IM, Becker JC, Straten PT, (2007) The universal character of the tumor-associated antigen survivin. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 5991-5994.
14. Straten P, Andersen MH, (2010) The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget 1: 239-245.
15. Riker A, Cormier J, Panelli M, Kammula U, Wang E, et al. (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112-120.
16. Campoli M, Chang CC, Ferrone S, (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20Suppl 4: A40-45.
17. Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, et al. (2012) Genome organizing function of SATB1 in tumor progression. Seminars in cancer biology.
18. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T, (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452: 187-193.
19. Zhao XD, Ji WY, Zhang W, He LX, Yang J, et al. (2010) Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL; journal for oto-rhino-laryngology and its related specialties 72: 1-5.
20. Mokhtar NM, Ramzi NH, Yin-Ling W, Rose IM, Hatta Mohd Dali AZ, et al. (2012) Laser capture microdissection with genome-wide expression profiling displayed gene expression signatures in endometrioid endometrial cancer. Cancer investigation 30: 156-164.
21. Tu W, Luo M, Wang Z, Yan W, Xia Y, et al. (2012) Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver international: official journal of the International Association for the Study of the Liver 32: 1064-1078.
22. Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, et al. (2012) Correlation of SATB1 overexpression with the progression of human rectal cancer. International journal of colorectal disease 27: 143-150.
23. Chen H, Takahara M, Oba J, Xie L, Chiba T, et al. (2011) Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. Journal of dermatological science 64: 39-44.
24. Cheng C, Lu X, Wang G, Zheng L, Shu X, et al. (2010) Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 118: 855-863.
25. Lu X, Cheng C, Zhu S, Yang Y, Zheng L, et al. (2010) SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncology reports 24: 981-987.
26. Xiang J, Zhou L, Li S, Xi X, Zhang J, et al. (2012) AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma. Oncology letters 3: 865-870.
27. Mir R, Pradhan SJ, Galande S (2012) Chromatin organizer SATB1 as a novel molecular target for cancer therapy. Current drug targets.
28. Zhou LY, Liu F, Tong J, Chen QQ, Zhang FW, (2009) [Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 29: 534-537.
29. Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, et al. (2012) Upregulation of SATB1 is associated with the development and progression of glioma. Journal of translational medicine 10: 149.
30. Fogh J, Wright WC, Loveless JD, (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. Journal of the National Cancer Institute 58: 209-214.
31. Fogh J, Trempe G (1975) New human tumor cell lines; Fogh J, editor. New York: Plenum Publishing Corp.
32. Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, et al. (1996) Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 87: 3429-3436.
33. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, et al. (1996) Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87: 3418-3428.
34. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF, (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proceedings of the National Academy of Sciences of the United States of America 98: 3964-3969.
35. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, et al. (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25: 2823-2831.
36. Hammond AS, Klein MR, Corrah T, Fox A, Jaye A, et al. (2005) Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes. Clinical and experimental immunology 140: 109-116.
37. Matsueda S, Wang M, Weng J, Li Y, Yin B, et al. (2012) Identification of prostate-specific g-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PloS one 7: e45756.
38. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA, (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of immunotherapy 26: 332-342.
39. Weng J, Ma W, Mitchell D, Zhang J, Liu M, (2005) Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors. Journal of cellular biochemistry 96: 1034-1048.
40. Van den Eynde BJ, Boon T, (1997) Tumor antigens recognized by T lymphocytes. International journal of clinical & laboratory research 27: 81-86.
41. Boon T, Coulie PG, Van den Eynde B, (1997) Tumor antigens recognized by T cells. Immunology today 18: 267-268.
42. Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, et al. (2006) Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Molecular cell 22: 231-243.
43. Yamayoshi A, Yasuhara M, Galande S, Kobori A, Murakami A, (2011) Decoy-DNA against special AT-rich sequence binding protein 1 inhibits the growth and invasive ability of human breast cancer. Oligonucleotides 21: 115-121.
44. Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, et al. (2001) Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. The Journal of experimental medicine 194: 1-12.
45. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, et al. (2000) The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes & development 14: 521-535.
46. Fessing MY, Mardaryev AN, Gdula MR, Sharov AA, Sharova TY, et al. (2011) p63 regulates Satb1 to control tissue-specific chromatin remodeling during development of the epidermis. The Journal of cell biology 194: 825-839.
47. Savarese F, Davila A, Nechanitzky R, De La Rosa-Velazquez I, Pereira CF, et al. (2009) Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. Genes & development 23: 2625-2638.